Consent Expiry Extensions, Collaborations, Grants, Conference Presentations, and FDA Approvals - Analyst Notes on Forest Laboratories, Intuitive Surgical, Horizon Pharma, Cubist and BDSI

NEW YORK, June 12, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Forest Laboratories, Inc. (NYSE: FRX), Intuitive Surgical, Inc. (NASDAQ: ISRG), Horizon Pharma Inc (NASDAQ: HZNP), Cubist Pharmaceuticals Inc (NASDAQ: CBST) and BioDelivery Sciences International, Inc. (NASDAQ: BDSI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3640-100free.

Forest Laboratories, Inc. Analyst Notes

On June 9, 2014, Forest Laboratories, Inc. (Forest Laboratories) announced that it has extended the expiration of the Company's consent solicitations from June 6, 2014 at 5:00 p.m. New York City time to June 12, 2014 at 5:00 p.m. New York City time. According to the Company, this move is to eliminate existing registration rights obligations regarding its outstanding debt securities (FRX Notes) of 4.375% senior notes due 2019, 4.875% senior notes due 2021, and 5.00% senior notes due 2021, with aggregate principal amounts of $1.05 billion, $750 million, and $1.2 billion, respectively, in exchange for the offer by Actavis plc to guarantee each of the FRX Notes. Forest Laboratories reported that as of June 9, 2014, a majority of holders of each series of FRX Notes had delivered consents pursuant to the Consent Solicitations. The full analyst notes on Forest Laboratories are available to download free of charge at:

http://www.analystsreview.com/Jun-12-2014/FRX/report.pdf

Intuitive Surgical, Inc. Analyst Notes

On June 9, 2014, Intuitive Surgical, Inc. (Intuitive Surgical) announced that it will provide financial support to a group of industry supporters of a new clinical outcomes registry called the Society of Gynecologic Oncology (SGO) Clinical Outcomes Registry or SGO COR. According to the Company, this new database will be managed by the SGO to support the efforts of those who are working to improve women's healthcare through comparative effectiveness research. The Company added that the researchers can also access SGO COR for comparison of surgery and treatment-related date for endometrial, ovarian, and cervical cancer. Being one of several industry supporters, Intuitive Surgical will only provide financial support but will not have input or control over SGO COR data. The full analyst notes on Intuitive Surgical are available to download free of charge at:

http://www.analystsreview.com/Jun-12-2014/ISRG/report.pdf

Horizon Pharma Inc Analyst Notes

On June 6, 2014, the Compensation Committee of the Board of Horizon Pharma Inc (Horizon Pharma) granted inducement awards to five new non-executive employees to purchase up to 143,800 shares of Horizon Pharma's common stock with an exercise price per share of $14.48, the fair market value on the grant date that will vest over four years with 25% of the underlying shares vesting after a year and an additional 1/48th of the underlying shares vesting monthly thereafter, given that the employee remains with the Company through each vesting date. The Compensation Committee also granted restricted stock unit awards to two out of the five new non-executive employees representing the right to receive up to 104,800 shares of Horizon Pharma's common stock, with 1/4th of the shares subject to the award vesting on each anniversary of the grant date, given that the employee continues service through each vesting date. The full analyst notes on Horizon Pharma are available to download free of charge at:

http://www.analystsreview.com/Jun-12-2014/HZNP/report.pdf

Cubist Pharmaceuticals Inc Analyst Notes

On June 2, 2014, Cubist Pharmaceuticals Inc (Cubist) announced that its President and Chief Operating Officer, Robert Perez, and Senior Vice President and CFO, Michael Tomsicek, will present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25, 2014, at 1:30 p.m. ET, at the Westin New York Grand Central in New York City. According to the Company, the presentation can be accessed live at Cubist's website and will be available there for 30 days after the presentation. The full analyst notes on Cubist are available to download free of charge at:

http://www.analystsreview.com/Jun-12-2014/CBST/report.pdf

BioDelivery Sciences International, Inc. Analyst Notes

On June 9, 2014, BioDelivery Sciences International, Inc. (BDSI) announced that it received approval from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII), which is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan that includes counseling and psychosocial support. BDSI reported that it expects to launch BUNAVAIL in late Q3 2014. Dr. Mark A. Sirgo, President and CEO of BDSI said, "FDA's approval of BUNAVAIL is another example of how we are creating products to help patients in their battle to overcome debilitating medical issues such as opioid dependence and is a tribute to the dedication and focus of our employees." The full analyst notes on BDSI are available to download free of charge at:

http://www.analystsreview.com/Jun-12-2014/BDSI/report.pdf

About Analysts Review

We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsReview.com

SOURCE Analysts Review